PMADS

Id:	acc0211
Group:	2sens
Protein:	STAT1
Gene Symbol:	STAT1
Protein Id:	P42224
Protein Name:	STAT1_HUMAN
PTM:	phosphorylation
Site:	Tyr727
Site Sequence:	QTTDNLLPMSPEEFDEVSRIV
Disease Category:	Cancer
Disease:	Medulloblastoma
Disease Subtype:
Disease Cellline:	TE671
Disease Info:
Drug:	ISG15 OV
Drug Info:	"Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, used in the treatment of various cancers including melanoma, non-small cell lung cancer, and classical Hodgkin lymphoma. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of ovarian, breast, pancreatic, and prostate cancers with specific genetic mutations, such as BRCA1/2."
Effect:	modulate
Effect Info:	"Overexpression of ISG15 promoted the phosphorylation of IRF - 3 (Ser396), JAK2 (Tyr1007/1008), and STAT1 (Ser727), thereby reducing the cytopathic effects induced by JEV."
Note:	Non-conventional drugs
Score:	3.0
Pubmed(PMID):	20035788
Sentence Index:	20035788_4-5
Sentence:	"ISG15 over-expression in human medulloblastoma cells significantly reduced the JEV-induced cytopathic effect and inhibited JEV replication by reducing the viral titers and genomes (p<0.05, Student's t-test); it also increased activation of the interferon stimulatory response element (ISRE)-luciferase cis-acting reporter in JEV-infected cells (p<0.05, Chi-square test). Furthermore, Western blotting revealed that ISG15 over-expression increased phosphorylation of IRF-3 (Ser396), JAK2 (Tyr1007/1008) and STAT1 (Tyr701 and Ser727) in JEV-infected cells (P<0.05, Chi-square test)."

Sequence & Structure:

MSQWYELQQLDSKFLEQVHQLYDDSFPMEIRQYLAQWLEKQDWEHAANDVSFATIRFHDLLSQLDDQYSRFSLENNFLLQHNIRKSKRNLQDNFQEDPIQMSMIIYSCLKEERKILENAQRFNQAQSGNIQSTVMLDKQKELDSKVRNVKDKVMCIEHEIKSLEDLQDEYDFKCKTLQNREHETNGVAKSDQKQEQLLLKKMYLMLDNKRKEVVHKIIELLNVTELTQNALINDELVEWKRRQQSACIGGPPNACLDQLQNWFTIVAESLQQVRQQLKKLEELEQKYTYEHDPITKNKQVLWDRTFSLFQQLIQSSFVVERQPCMPTHPQRPLVLKTGVQFTVKLRLLVKLQELNYNLKVKVLFDKDVNERNTVKGFRKFNILGTHTKVMNMEESTNGSLAAEFRHLQLKEQKNAGTRTNEGPLIVTEELHSLSFETQLCQPGLVIDLETTSLPVVVISNVSQLPSGWASILWYNMLVAEPRNLSFFLTPPCARWAQLSEVLSWQFSSVTKRGLNVDQLNMLGEKLLGPNASPDGLIPWTRFCKENINDKNFPFWLWIESILELIKKHLLPLWNDGCIMGFISKERERALLKDQQPGTFLLRFSESSREGAITFTWVERSQNGGEPDFHAVEPYTKKELSAVTFPDIIRNYKVMAAENIPENPLKYLYPNIDKDHAFGKYYSRPKEAPEPMELDGPKGTGYIKTELISVSEVHPSRLQTTDNLLPMSPEEFDEVSRIVGSVEFDSMMNTV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

STAT1-Ser127
Cancer	Intensity
BRCA	-1.111
COAD
HGSC
ccRCC
GBM
HNSC	0.281
LUAD
LUSC	0.829
non_ccRCC
PDAC
UCEC

STAT1-Ser162
Cancer	Intensity
BRCA	-0.117
COAD
HGSC
ccRCC	-0.025
GBM	1.015
HNSC	-0.463
LUAD	0.053
LUSC	-1.995
non_ccRCC	0.225
PDAC
UCEC	1.307

STAT1-Ser532
Cancer	Intensity
BRCA	-1.146
COAD	0.265
HGSC	2.521
ccRCC	-0.306
GBM	0.079
HNSC	-0.783
LUAD	0.212
LUSC	0.216
non_ccRCC	-0.093
PDAC	-1.183
UCEC	0.22

STAT1-Ser640
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.628
GBM	1.009
HNSC	0.442
LUAD	-0.81
LUSC	-1.225
non_ccRCC	1.22
PDAC	0.93
UCEC	-0.939

STAT1-Ser708
Cancer	Intensity
BRCA	-0.707
COAD
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

STAT1-Ser727
Cancer	Intensity
BRCA	0.237
COAD	0.528
HGSC	-2.013
ccRCC	-0.034
GBM	1.48
HNSC	0.35
LUAD	0.26
LUSC	0.618
non_ccRCC	-1.678
PDAC	0.093
UCEC	0.159

STAT1-Thr540
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	727	U	Colorectal cancer	Phosphorylation	33747209
S	727	U	Nephroblastoma	Phosphorylation	16799645

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb